Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Selective HDAC inhibition for the disruption of latent HIV-1 infection.

Barton KM, Archin NM, Keedy KS, Espeseth AS, Zhang YL, Gale J, Wagner FF, Holson EB, Margolis DM.

PLoS One. 2014 Aug 19;9(8):e102684. doi: 10.1371/journal.pone.0102684. eCollection 2014.

2.

Epigenetic silencing of HIV-1 by the histone H3 lysine 27 methyltransferase enhancer of Zeste 2.

Friedman J, Cho WK, Chu CK, Keedy KS, Archin NM, Margolis DM, Karn J.

J Virol. 2011 Sep;85(17):9078-89. doi: 10.1128/JVI.00836-11. Epub 2011 Jun 29.

3.

Therapy for persistent HIV.

Keedy KS, Margolis DM.

Trends Pharmacol Sci. 2010 May;31(5):206-11. doi: 10.1016/j.tips.2010.02.001. Epub 2010 Mar 5. Review.

4.

Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors.

Archin NM, Keedy KS, Espeseth A, Dang H, Hazuda DJ, Margolis DM.

AIDS. 2009 Sep 10;23(14):1799-806. doi: 10.1097/QAD.0b013e32832ec1dc.

5.

A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression.

Keedy KS, Archin NM, Gates AT, Espeseth A, Hazuda DJ, Margolis DM.

J Virol. 2009 May;83(10):4749-56. doi: 10.1128/JVI.02585-08. Epub 2009 Mar 11.

Supplemental Content

Loading ...
Support Center